> Reagents, Molecular Assay, Gene Anomaly, Mutation, CYP2D6
Reagents, Molecular Assay, Gene Anomaly, Mutation, CYP2D6
Definition : Molecular assay reagents intended to identify mutations in cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) gene, located at chromosome 22q13.1, which is responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. The gene is involved in the metabolism of drugs such as antiarrhythmics, adrenoreceptor antagonists, and tricyclic antidepressants. Mutations at this locus have been identified in patients with poor metabolism of drugs, early-onset Parkinson's disease, ankylosing spondylitis, and leukemia.
Entry Terms : "Debrisoquine Sensitivity Gene Mutation Detection Reagents" , "Poor Drug Metabolism Gene Mutation Detection Reagents" , "CYP2D6 Gene Mutation Detection Reagents"
UMDC code : 24380
Our newly expanded portfolio of market-leading lab services can provide your high-performance lab with a comprehensive suite of services, or just the ones you want. From business consulting and protocol development, to instrument repair and optimization, our services can help you increase your lab's productivity and efficiency.
Focus Diagnostics Inc
As part of the Quest Diagnostics family, Focus Diagnostics, Inc. is committed to providing proven and reliable products its customers have grown accustomed to throughout the years. Since its founding in 1978, Focus Diagnostics has grown its business from specialized laboratory testing to manufacturing its high-quality laboratory tests for hospitals and commercial laboratories worldwide. These manufactured tests are built in response to diagnostic testing trends identified and evaluated by Focus Diagnostics and used in Quest Diagnostics' national laboratories.
Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.
Gen-Probe Life Sciences Ltd
Gen-Probe Life Sciences Ltd
Innogenetics NV is an international diagnostic company that develops and markets diagnostic products to improve therapy management and patient health.
Luminex Corporation (NASDAQ: LMNX) was incorporated in May 1995 and began commercial production of our first generation system in 1997. Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the diagnostic and life science industries.
QIAGEN is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.